The Proteoform Landscape of Tau from the Human Brain
- 21 May 2025
- journal article
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 24 (6) , 2916-2925
Abstract
Tau is a microtubule-associated protein (MAP) and is critical for maintaining the cytoskeleton of neurons. Tau and its post-translational modifications (PTMs) have been studied for decades, yet the exact composition of intact tau and its truncation products present in the human brain has evaded study at the proteoform level. Here, we show that tau proteoform profiling and exact characterization are possible using immunoprecipitation (IP) and the new approach of individual ion mass spectrometry (I2MS). We provide a first glimpse of the tau proteoform landscape present in the CHAPS-soluble extracts from the temporal cortex of a control subject and a donor with Alzheimer's disease (AD). Profiling and identification of four isoforms (0N3R, 1N3R, 0N4R, and 1N4R), truncated products (e.g., 72-172 derived from the 0N3R/0N4R isoforms), and intact tau proteoforms harboring PTMs include phosphorylation, methylation, and acetylation. The specific tau proteoform identification typically employs proton transfer charge reduction (PTCR) and electron transfer dissociation (ETD) with spectral readout by individual ion tandem mass spectrometry (I2MS2). A precise understanding of the tau proteoform landscape over the course of neurodegeneration is critical to understand AD pathology vs related dementias. The assay approach reported here will advance AD research, gives a sense of what is technologically possible for new biomarker discovery and will assist the development of therapeutics using the most exact kind of compositional information on tau.Keywords
Funding Information
- National Institutes of Health (P30 AG072977, P30 CA060553, P30 DA018310, S10OD025194)
- National Resource for Translational and Developmental Proteomics (P41 GM108569)
This publication has 47 references indexed in Scilit:
- Complicated Role of Post-translational Modification and Protease-Cleaved Fragments of Tau in Alzheimer’s Disease and Other TauopathiesMolecular Neurobiology, 2023
- The Role of Post-Translational Modifications on the Structure and Function of Tau ProteinJournal of Molecular Neuroscience, 2022
- Tau phosphorylation sites serine202 and serine396 are differently altered in chronic traumatic encephalopathy and Alzheimer's diseaseAlzheimer's & Dementia, 2021
- Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance studyThe Lancet Neurology, 2021
- A current view on Tau protein phosphorylation in Alzheimer's diseaseCurrent Opinion in Neurobiology, 2021
- Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer’s DiseaseCell, 2020
- Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's diseaseNeurobiology of Disease, 2019
- STORI Plots Enable Accurate Tracking of Individual Ion SignalsJournal of the American Society for Mass Spectrometry, 2019
- Assessments of the accumulation severities of amyloid β-protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer's brainsNeurobiology of Disease, 2006
- Anomalously phosphorylated tau and Aβ fragments in the CSF correlates with cognitive impairment in MCI subjectsNeurobiology of Aging, 2006